The efficacy of placebo for the treatment of cancer-related fatigue: a systematic review and meta-analysis
| العنوان: | The efficacy of placebo for the treatment of cancer-related fatigue: a systematic review and meta-analysis |
|---|---|
| المؤلفون: | Carmelia Maria Noia Barreto, Auro Del Giglio, Pedro Nazareth Aguiar, Daniel de Iracema Gomes Cubero |
| المصدر: | Supportive Care in Cancer. 28:1755-1764 |
| بيانات النشر: | Springer Science and Business Media LLC, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Palliative care, Psychological intervention, Placebo, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Internal medicine, medicine, Clinical endpoint, Humans, Prospective Studies, 030212 general & internal medicine, Cancer-related fatigue, Fatigue, Physical Therapy Modalities, Response rate (survey), Clinical Trials as Topic, business.industry, Cancer, medicine.disease, Placebo Effect, Clinical trial, Treatment Outcome, 030220 oncology & carcinogenesis, Meta-analysis, Chronic Disease, medicine.symptom, business |
| الوصف: | e23157 Background: Cancer-related fatigue (CRF) is a common symptom among patients with cancer. The efficacy of placebo, however, was never the main objective of any meta-analysis. Predicting the efficacy of placebo may facilitate researchers in designing future clinical trials for the treatment of CRF. Methods: We performed a systematic review searching for prospective clinical trials comparing any treatment versus placebo for the treatment of CRF. We included studies that enrolled patients with any primary site of neoplasia and any stage of cancer. We excluded all studies that assessed fatigue related to any treatment. The primary endpoint of this study is the mean effect of placebo on fatigue according to the Functional Assessment of Chronic Illness (FACIT-F) and Brief Fatigue Inventory (BFI) scales. The secondary endpoint was the proportion of patients who reported improvement in fatigue (response rate). Results: We found 520 studies, and 29 studies with 3,758 participants were included in the meta-analysis. Placebo had a mean effect of +4.88 (95%CI +2.45 to +7.29) using the FACIT-F scale, although it was statistically worse than the interventions studied (p = 0.005). Using the BFI scale, placebo had an average effect of +0.64 (95%CI +0.02 to +1.30), although it was also worse than the other interventions studied (p = 0.002). In terms of the response rate, 29% (95%CI 25%–32%) of patients taking a placebo reported a significant improvement in CRF compared to 36% of patients treated with other interventions (p = 0.030). Conclusions: Placebo treatments had a significant effect on CRF, and predicting these effects may help design future studies for CRF. |
| تدمد: | 1433-7339 0941-4355 |
| DOI: | 10.1007/s00520-019-04977-w |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a280f35b8b22218552a3f51e2a0e8fd https://doi.org/10.1007/s00520-019-04977-w |
| Rights: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....7a280f35b8b22218552a3f51e2a0e8fd |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14337339 09414355 |
|---|---|
| DOI: | 10.1007/s00520-019-04977-w |